Catalyst
Slingshot members are tracking this event:
Phase 2b data of Aldoxorubicin for relapsed/refractory small cell lung cancer due Q1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CYTR |
|
|
||||
Additional Information
- Currently anticipate reporting top-line results from the global Phase 2b clinical trial evaluating aldoxorubicin in patients with second-line small cell lung cancer (SCLC) in the fourth quarter of 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 03, 2017
Occurred Source:
https://cytrxcorporation.gcs-web.com/news-releases/news-release-details/cytrx-reports-second-quarter-2017-financial-results?field_nir_news_date_value%5Bmin%5D=2017&items_per_page=10#views-exposed-form-widget-news-widget-news-ul
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2b Data, Aldoxorubicin, Refractory Small Cell Lung Cancer, 2h 2016, Kaposi's Sarcoma
